Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

Rhea-AI Summary

OSR Holdings (NASDAQ:OSRH) announced that subsidiary Woori IO signed a mutual NDA with Sinopharm on March 19, 2026 to exchange confidential information about Woori IO's noninvasive near-infrared (NIR) glucose monitoring technology.

The NDA enables evaluation of regulatory, clinical, and commercial pathways in China. Sinopharm reported 2024 revenue of approximately USD 81 billion. China has over 140 million people with diabetes and the device market could exceed $12 billion by 2032, highlighting potential commercial opportunity amid early-stage discussions.

Positive

• NDA signed with Sinopharm on March 19, 2026
• Sinopharm reported $81 billion revenue in 2024
• China diabetes population >140 million (large addressable market)
• China diabetes device market projected >$12 billion by 2032

Negative

• Discussions are preliminary with no binding commercial terms disclosed
• Regulatory and clinical pathways in China remain uncertain
• Potential need for global multicenter trials could delay commercialization

News Market Reaction – OSRH

+2.35%

10 alerts

+2.35% Session close to close

-16.1% Trough in 31 hr 36 min

$12.07M Market Cap

0.9x Rel. Volume

In the Mar 19 session, OSRH gained 2.35%, reflecting a moderate positive market reaction. Argus tracked a trough of -16.1% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights an NDA between Woori IO and Sinopharm to evaluate regulatory, clinical,...

Analysis

This announcement highlights an NDA between Woori IO and Sinopharm to evaluate regulatory, clinical, and commercial pathways for noninvasive glucose monitoring in China. Partnering discussions involve a distributor with reported $81 billion in 2024 revenue and a market where an estimated 140 million people live with diabetes. In context of OSRH’s recent Woori IO acquisition and FDA-driven dual-track strategy, investors may watch for concrete agreements, trial designs, and any China-specific regulatory milestones.

Key Figures

Sinopharm revenue: $81 billion China diabetes population: 140 million people China diabetes device market: $12 billion +5 more

8 metrics

Sinopharm revenue $81 billion Reported 2024 revenue for Sinopharm Group

China diabetes population 140 million people Estimated diabetes prevalence in China

China diabetes device market $12 billion Projected market size by 2032

Current share price $0.4332 Price before NDA news on Mar 19, 2026

1-day price change -3.95% Change over prior 24 hours pre-news

52-week high $4.33 52-week high price level

52-week low $0.3803 52-week low price level

Market capitalization $11,552,755 Equity value pre-news

Historical Context

5 past events · Latest: Mar 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 05	Nasdaq extension, strategy	Positive	+14.7%	Nasdaq bid-price extension and reiteration of large VXM01 licensing potential.
Feb 02	Shareholder update	Positive	-4.3%	CEO update on Nasdaq timing, VXM01 term sheet, and device merger plans.
Jan 27	Woori IO acquisition	Positive	-3.9%	Completion of Woori IO acquisition and review of device subsidiary combination.
Jan 22	FDA wearable clarification	Positive	+10.2%	FDA guidance enabling two-phase commercialization of Woori IO wearables and CGM.
Jan 16	CSO appointment	Positive	-4.4%	Vaximm appointing a CSO to advance the VXM01 oral immunotherapy platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed to negative price reactions to largely positive strategic news, with several divergences where shares fell on constructive updates.

Recent Company History

Over the last few months, OSR Holdings has focused on Nasdaq compliance, strategic licensing, and building its device platform. A 180-day Nasdaq extension and VXM01 licensing discussions (up to $30M upfront and $815M milestones) highlighted non-dilutive optionality. Woori IO’s acquisition and FDA clarification on non-medical wearables supported a dual-track commercialization plan. Today’s NDA with Sinopharm extends that trajectory by targeting China distribution and regulatory pathways for Woori IO’s noninvasive glucose monitoring technology.

Key Terms

non-disclosure agreement, regulation fd, near-infrared, continuous glucose monitoring, +1 more

5 terms

non-disclosure agreement regulatory

"has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group"

A non-disclosure agreement is a legal contract that prevents one or more parties from sharing confidential information with others. It matters to investors because it helps protect sensitive business details, ensuring that important information remains private and cannot be used against the company or its partners. Think of it as a formal promise to keep certain information secret, similar to a trust between friends about a surprise gift.

regulation fd regulatory

"This announcement is being made in accordance with Regulation FD to ensure broad"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

near-infrared medical

"noninvasive near-infrared (NIR) glucose monitoring technology, allowing both parties"

Near-infrared is the band of light just beyond what the human eye can see, similar to a flashlight beam shifted slightly into a color you can’t perceive. It penetrates materials and tissue differently than visible light, so it’s widely used in medical imaging, sensors, remote sensing and quality-control tools; for investors, that means technologies using near-infrared can enable new products, regulatory pathways and revenue streams tied to diagnostics, monitoring and industrial inspection.

continuous glucose monitoring medical

"offering noninvasive, needle-free continuous glucose monitoring without the pain"

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

multicenter trials medical

"including potential global multicenter trials."

Research studies that run the same medical test or treatment at multiple hospitals or clinics at the same time, like trying a recipe in several different kitchens to see if it works broadly. For investors, multicenter trials matter because they usually involve larger patient groups and more varied conditions, which makes results more reliable, lowers the chance of surprising failures, and influences regulatory approval and commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China. This announcement is being made in accordance with Regulation FD to ensure broad, non-exclusionary public dissemination of this information.

The NDA establishes a formal framework for Woori IO and Sinopharm to exchange confidential information relating to Woori IO's noninvasive near-infrared (NIR) glucose monitoring technology, allowing both parties to evaluate potential regulatory, clinical, and commercial pathways in China. Sinopharm Group, with reported 2024 revenue of approximately USD 81 billion, is generally considered China's largest pharmaceutical and medical device distributor with the most extensive nationwide network.

China represents one of the world's largest and fastest-growing diabetes markets, with more than 140 million people estimated to be living with the disease and rising demand for convenient glucose monitoring solutions. China's diabetes device market is projected to expand significantly over the next decade, potentially exceeding $12 billion by 2032, according to a report by Research and Markets, as adoption of advanced glucose monitoring technologies accelerates. Woori IO's proprietary NIR optical sensing technology addresses this demand directly, offering noninvasive, needle-free continuous glucose monitoring without the pain and adoption barriers of conventional invasive methods.

"China is a highly compelling market, given its large and growing diabetes population and increasing adoption of advanced glucose monitoring technologies," said Peter Hwang, CEO of OSR Holdings. "Our engagement with Sinopharm reflects the strategic importance of the China market and the potential role that established national distribution platforms may play in enabling future commercialization. While still at an early stage, this engagement underscores the broader global interest in Woori IO's noninvasive glucose monitoring platform."

Woori IO has received additional interest from healthcare organizations, pharmaceutical companies, and distribution partners across multiple regions, highlighting growing recognition of its noninvasive glucose monitoring platform and strong demand for more accessible, patient-friendly solutions. "Our NDA with Sinopharm allows us to begin evaluating potential regulatory and commercial pathways in China while continuing discussions with partners in other regions," said Sunkie Park, CEO of Woori IO. "These interactions could help shape future clinical development programs, including potential global multicenter trials."

While discussions remain preliminary, OSR Holdings intends to actively pursue strategic partnerships across major international markets as it advances development, regulatory strategy, and potential commercialization pathways for this next-generation glucose monitoring technology, which could represent a transformational step forward in improving accessibility and convenience in diabetes care globally.

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at www.OSR-Holdings.com.

About Woori IO Co., Ltd.

Woori IO is a South Korea-based medical device company developing noninvasive biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking and is designed for integration into wearables. The company has been recognized by a leading global consumer electronics company's startup program for its innovation in NIGM technology. Learn more at www.woori.io.

Contact:

Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding potential collaboration opportunities, anticipated commercialization pathways, regulatory strategy, global market demand for noninvasive CGM technology, and future business prospects. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect future results include, but are not limited to, the ability to enter into definitive agreements with prospective partners, regulatory approvals, product development outcomes, market acceptance, competitive developments, capital market conditions, and other risks described in OSR Holdings' filings with the U.S. Securities and Exchange Commission. OSR Holdings undertakes no obligation to update forward-looking statements except as required by law.

SOURCE: OSR Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

What does the Woori IO NDA with Sinopharm (OSRH) mean for China commercialization?

It formalizes confidential information exchange to evaluate China pathways. According to the company, the NDA lets both parties assess regulatory, clinical, and commercial options while discussions remain at an early exploratory stage.

When did OSR Holdings announce the Woori IO NDA with Sinopharm (OSRH)?

The announcement was made on March 19, 2026. According to the company, the disclosure was issued under Regulation FD to ensure broad public dissemination of the NDA.

How large is the China market opportunity cited by OSR Holdings for Woori IO (OSRH)?

China has over 140 million people with diabetes and a growing device market. According to the company, Research and Markets projects the China diabetes device market could exceed $12 billion by 2032.

What technology is Woori IO evaluating with Sinopharm under the NDA (OSRH)?

Woori IO's noninvasive near-infrared (NIR) optical sensing glucose monitoring. According to the company, the technology aims to enable needle-free continuous glucose monitoring without invasive sensors.

Does the NDA with Sinopharm commit to sales or distribution in China for Woori IO (OSRH)?

No, the NDA does not commit to sales or distribution. According to the company, it only creates a framework to exchange confidential information and evaluate potential regulatory and commercial pathways.